指南与共识炎症性肠病胃肠动力与功能性疾病

系统综述:益生菌在下消化道症状管理中的应用——更新版国际循证共识

Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus.
指南 / 共识 · Aliment Pharmacol Ther · 2018-02-20

本更新版系统综述纳入2012年1月至2017年6月发表的随机安慰剂对照试验共70项,由8位专家小组通过德尔菲共识重新评估既往声明。共识指出特定益生菌可减轻部分肠易激综合征(IBS)患者的整体症状负担和腹痛,减少抗生素或幽门螺杆菌根除治疗相关腹泻的持续时间和强度,且安全性良好。

要点

  • 特定益生菌可减轻部分IBS患者的整体症状负担和腹痛,证据等级为高,共识度100%。
  • 特定益生菌可减少抗生素或幽门螺杆菌根除治疗相关腹泻的持续时间和强度,安全性良好。
  • 部分IBS患者中特定益生菌可减轻腹胀/腹部膨隆并改善排便频率/性状,证据等级为中等。

核心结论

  • 更新版综述表明特定益生菌对某些下消化道问题有益,尽管许多新发表文献未报告益生菌的获益,可能因纳入新的、效力较低的制剂。
  • 特定益生菌可缓解IBS的下消化道症状,预防抗生素和幽门螺杆菌根除治疗相关腹泻,并显示良好的安全性。
  • 本研究有助于临床医生针对特定症状推荐/处方益生菌。

研究设计与样本

  • 系统综述纳入2012年1月至2017年6月发表的随机安慰剂对照试验;由8位专家小组重新评估既往声明,并通过德尔菲共识达成一致。

主要发现

  • 共纳入70项研究,其中IBS 34项、抗生素相关腹泻13项、幽门螺杆菌根除治疗相关腹泻7项、其他情况16项。
  • 在15项以整体IBS症状为主要终点的研究中,8项报告益生菌相比安慰剂有显著获益。
  • 共识度100%且证据等级为「高」的声明指出:特定益生菌有助于减轻部分IBS患者的整体症状负担和腹痛,减少接受抗生素或幽门螺杆菌根除治疗患者腹泻的持续时间和强度,且安全性良好。
  • 共识度70%–100%且证据等级为「中等」的声明指出:在部分IBS患者中,特定益生菌有助于减轻腹胀/腹部膨隆并改善排便频率/性状。

局限性

  • 许多新发表文献未报告益生菌的获益,可能因纳入新的、效力较低的制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2013, a systematic review and Delphi consensus reported that specific probiotics can benefit adult patients with irritable bowel syndrome (IBS) and other gastrointestinal (GI) problems. AIM: To update the consensus with new evidence. METHODS: A systematic review identified randomised, placebo-controlled trials published between January 2012 and June 2017. Evidence was graded, previously developed statements were reassessed by an 8-expert panel, and agreement was reached via Delphi consensus. RESULTS: A total of 70 studies were included (IBS, 34; diarrhoea associated with antibiotics, 13; diarrhoea associated with Helicobacter pylori eradication therapy, 7; other conditions, 16). Of 15 studies that examined global IBS symptoms as a primary endpoint, 8 reported significant benefits of probiotics vs placebo. Consensus statements with 100% agreement and "high" evidence level indicated that specific probiotics help reduce overall symptom burden and abdominal pain in some patients with IBS and duration/intensity of diarrhoea in patients prescribed antibiotics or H. pylori eradication therapy, and have favourable safety. Statements with 70%-100% agreement and "moderate" evidence indicated that, in some patients with IBS, specific probiotics help reduce bloating/distension and improve bowel movement frequency/consistency. CONCLUSIONS: This updated review indicates that specific probiotics are beneficial in certain lower GI problems, although many of the new publications did not report benefits of probiotics, possibly due to inclusion of new, less efficacious preparations. Specific probiotics can relieve lower GI symptoms in IBS, prevent diarrhoea associated with antibiotics and H. pylori eradication therapy, and show favourable safety. This study will help clinicians recommend/prescribe probiotics for specific symptoms.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hungin APS, Mitchell CR, Whorwell P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. Aliment Pharmacol Ther. 2018. PMID: 29460487. doi:10.1111/apt.14539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。